Platform & Pipeline
Our platform consists of three fundamental elements:
The 14-3-3 encyclopedia provides a systematic understanding of the 14-3-3:client interface so that we can achieve predictive, efficient structure-chemotype pairing in a modular fashion, substantially streamlining the drug discovery process. With an extensive client database of binding motifs and 14-3-3:client protein structures, we can more quickly identify the most promising candidates from our library of privileged scaffolds to begin the screening process.
Our pipeline currently focuses on oncology, where multiple opportunities exist to engage currently undrugged targets that are involved in oncogenic signaling and gene expression, cell cycle dysregulation, and other cancer-driving processes. With five programs in early discovery, we expect to field at least one development candidate by 2H 2023.